Skip to main content
SpringerLink
Log in

Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist

  • Published:
Current Psychosis & Therapeutics Reports

Abstract

The pharmacologic treatment of schizophrenia presents several challenges: 1) available treatments are incompletely and variably effective; 2) treatments take time to show their full effects; and 3) different benefits and adverse effects of treatment appear over different time frames. To aid in treatment decisions, clinicians are inundated with information that can be difficult to digest and integrate. Treatment often is provided within systems of care that limit the range of available treatment options. To preserve broad treatment options and facilitate optimal care, the State of Florida has developed a comprehensive program to provide several tools to the treating physician, and systems of care to promote optimally effective and efficient pharmacotherapy for each individual with schizophrenia. Although a formal evaluation of its effectiveness is underway, the program has been uniformly well received and considered to be very useful in helping clinicians and treatment systems efficiently provide schizophrenia patients with the best currently available pharmacologic treatment. Elements of the program and its evolution and operation are described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Psychiatric Association:Practice guideline for the treatment of patients with schizophrenia.Am J Psychiatry 2004,161(Suppl 2):1–56.

    Google Scholar 

  2. Nasrallah HA, Targum SD, Tandon R, et al.:Clinical effectiveness in the treatment of schizophrenia: an evolving paradigm.Psychiatr Serv 2005,56:273–282.

    Article  PubMed  Google Scholar 

  3. Lieberman JA, Murray RM:Comprehensive care of schizophrenia: a textbook of clinical management. London: Martin Dunitz; 2000.

    Google Scholar 

  4. Bustillo J, Lauriello J, Horan W, et al.:The psychosocial treatment of schizophrenia: an update.Am J Psychiatry 2001,158:163–175.

    Article  PubMed  CAS  Google Scholar 

  5. Bruen B, Ghosh A:Medicaid Prescription Drug Spending and Use. Kaiser Commission on Medicaid and the Uninsured, Washington D.C., 2005.

  6. Lehman AF, Steinwachs DS:Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations.Schizophr Bull 1998,24:1–10.

    PubMed  CAS  Google Scholar 

  7. President’s New Freedom Commission on Mental Health:Achieving the promise: transforming mental health care in America, final report. July 2003. http://www.mentalhealthcommission.gov/reports/reports.html

  8. Goldman HH, Azrin ST:Public policy and evidence-based practice.Psychiatr Clin North Am 2001,52:1591–1597.

    CAS  Google Scholar 

  9. Torrey WC, Drake RL, Dixon L, et al.:Implementing evidence-based practices for persons with severe mental illnesses.Psychiatr Services 2001,52:45–50.

    Article  CAS  Google Scholar 

  10. Ganguly R, Kotzan LA, Miller LS, et al.:Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients 1998–2000.J Clin Psychiatry 2004,65:1377–1388

    PubMed  Google Scholar 

  11. Miller AL, Hall CS, Buchanan RW, et al.:The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.J Clin Psychiatry 2004,65:500–508.

    PubMed  Google Scholar 

  12. McEvoy IP, Scheifler PL, Frances A:The expert consensus guideline series: treatment of schizophrenia 1999.J Clin Psychiatry 1999,60(Suppl 11):1–90.

    Google Scholar 

  13. Lehman AF, Buchanan RW, Dickerson FB, et al.:Evidence-based treatment for schizophrenia.Psychiatr Clin North Am 2003,26:939–954.

    Article  PubMed  Google Scholar 

  14. Mellman TA, Miller AL, Weissman EM, et al.:Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms.Psychiatr Serv, 2001,52:619–625.

    Article  PubMed  CAS  Google Scholar 

  15. Surles RC:Atypical antipsychotics: considerations for Medicaid coverage.Am J Manag Care 2005,11(Suppl):S248-S253.

    PubMed  Google Scholar 

  16. West JC, Wilk JE, Olfson M, et al.:Patterns and quality of treatment for patients with schizophrenia in routine clinical practice.Psychiatr Services 2005,56:283–291.

    Article  Google Scholar 

  17. Fixsen DL, Naoom SF, Blasé KA, et al.:Implementation Research: A synthesis of the literature. University of South Florida, FMHI Publication #231, Tampa, 2005.

  18. Tandon R, Fleischhacker WW:Comparative efficacy of antipsychotics in the treatment of schizophrenia.Schizophr Res 2005,79:145–155.

    Article  PubMed  Google Scholar 

  19. Leucht S, Pitschel-Walz G, Abraham D, et al.:Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo.Schizophr Res 1999,35:51–68.

    Article  PubMed  CAS  Google Scholar 

  20. Davis JM, Chen N, Glick ID:A meta-analysis of the efficacy of second-generation antipsychotics.Arch Gen Psychiatry 2003,60:553–564.

    Article  PubMed  CAS  Google Scholar 

  21. Lieberman JA, Stroup TS, McEvoy JP, et al.:Effectivesness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med 2005,353:1209–1223.

    Article  PubMed  CAS  Google Scholar 

  22. Kane J, Leucht S, Carpenter D, Docherty JP:Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.J Clin Psychiatry 2003,64(Suppl 12):5–19.

    PubMed  Google Scholar 

  23. Tandon R:Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr Q 2002,73:297–311.

    Article  PubMed  Google Scholar 

  24. Kane J, Honigfeld G, Singer J, et al.:Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine.Arch Gen Psychiatry 1988,45:789–796.

    PubMed  CAS  Google Scholar 

  25. Tandon R, Dewan NA, Constantine RJ, Wells J:Best practice pharmacological treatment of schizophrenia: Applying principles of evidence-based medicine.Curr Psychosis and Ther Report 2005,3:53–60.

    Google Scholar 

  26. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity:Consensus development conference on antipsychotic drugs and obesity and diabetes.J Clin Psychiatry 2004,65:267–272.

    Article  Google Scholar 

  27. Marder SR, Essock SM, Miller AL, et al.:Physical health monitoring of patients with schizophrenia.Am J Psychiatry 2004,161:1334–1349.

    Article  PubMed  Google Scholar 

  28. Parks J, Surles R:Using best practices to manage psychiatric medications under Medicaid.Psychiatr Serv 2004,55:1227–1229.

    Article  PubMed  Google Scholar 

  29. Lawrie SM, Scott AIF, Sharpe MC:Implementing evidence-based psychiatry: whose responsibility? Br J Psychiatry 2001,178:195–196.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Florida Mental Health Institute, University of South Florida, 13301 Bruce B. Downs Blvd., MHC 2724, 33612, Tampa, FL, USA

    Robert J. Constantine Ph.D

Authors
  1. Robert J. Constantine Ph.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sybil M. Richard RPh, JD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard C. Surles PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Medvedeff PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naakesh A. Dewan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lonnie Mann MSW
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Janis M. Williamson BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rajiv Tandon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Constantine Ph.D.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Constantine, R.J., Richard, S.M., Surles, R.C. et al. Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. Current Psychosis & Therapeutics Reports 4, 5–11 (2006). https://doi.org/10.1007/BF02629408

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02629408

Keywords

Search

Navigation